Orphan Medical
Registered Principal Details
Business Or Interest:
Pharmaceutical company.
Lobbying Interests:
Scheduling of controlled substances and controlled substance analogues, sexual assault statutes, controlled substances, regulated chemicals.
CEO Name:
John Bullion
Vice President, Commercial Operations
Pharmaceutical company.
Lobbying Interests:
Scheduling of controlled substances and controlled substance analogues, sexual assault statutes, controlled substances, regulated chemicals.
CEO Name:
John Bullion
Vice President, Commercial Operations
Contact
PS
Pam Stahl
13911 Ridgedale Drive Suite 250
Minnetonka, MN 55305
(952) 513-6900
(952) 541-9209
pstahl@orphan.com
13911 Ridgedale Drive Suite 250
Minnetonka, MN 55305
(952) 513-6900
(952) 541-9209
pstahl@orphan.com
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Administrative Rulemaking Proceedings
Agency Name
Controlled Substances Board
Subject
Delete gamma-butyrolactone (GBL) from s. 961.14 (5) (ag), Stats.
Scope Statement
Register Number: 548 (8/15/2001)
Clearinghouse Rule: CR 01-107
3/4/2002
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Comments
Attended controlled substances board meeting to answer questions about the descheduling of GBL and advocate for controlling 1,4 BD as well as discuss ways to allow FDA approved medical GHB for narcolepsy patients
Controlled Substances Board
Subject
Delete gamma-butyrolactone (GBL) from s. 961.14 (5) (ag), Stats.
Scope Statement
Register Number: 548 (8/15/2001)
Clearinghouse Rule: CR 01-107
Other
Notification Date3/4/2002
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Comments
Attended controlled substances board meeting to answer questions about the descheduling of GBL and advocate for controlling 1,4 BD as well as discuss ways to allow FDA approved medical GHB for narcolepsy patients
Schedule III classification of controlled substance drug products containing gamma–hydroxybutyric acid.
Agency Name
Controlled Substances Board
Subject
Schedule III classification of controlled substance drug products containing gamma–hydroxybutyric acid.
Scope Statement
Register Number: 563 (11/15/2002)
Clearinghouse Rule: CR 03-057
7/30/2004
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Controlled Substances Board
Subject
Schedule III classification of controlled substance drug products containing gamma–hydroxybutyric acid.
Scope Statement
Register Number: 563 (11/15/2002)
Clearinghouse Rule: CR 03-057
None
Notification Date7/30/2004
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
controlled substance analogues
controlled substance analogues
Action Intended To Affect
Both Legislative Matter and Rule
Notification Date
7/30/2003
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Both Legislative Matter and Rule
Notification Date
7/30/2003
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Total Lobbying Effort
| 2004 January - June |
2004 July - December |
Total | |
|---|---|---|---|
| Total Lobbying Expenditures | 2004 January - June $495.14 |
2004 July - December $588.00 |
Total $1,083.14 |
| Total Hours Communicating | 2004 January - June 1.96 |
2004 July - December 0.25 |
Total 2.21 |
| Total Hours Other | 2004 January - June 0.81 |
2004 July - December 3.00 |
Total 3.81 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
No legislative bills/resolutions found.
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
Schedule III classification of controlled substance drug products containing gamma–hydroxybutyric acid.
| 2003 January - June |
2003 July - December |
2004 January - June |
2004 July - December |
Total |
|---|---|---|---|---|
| 2003 January - June |
2003 July - December |
2004 January - June 55% |
2004 July - December |
Total 33% |
Topics Not Yet Assigned A Bill Or Rule Number
| 2003 January - June |
2003 July - December |
2004 January - June |
2004 July - December |
Total |
|---|---|---|---|---|
| 2003 January - June |
2003 July - December |
2004 January - June 45% |
2004 July - December 100% |
Total 75% |
Minor Efforts
No minor efforts found.
Other Matters
No other matters found.